Transgene's Therapeutic Vaccine TG4010, Phase IIb Data in Advanced Non-Small Cell Lung Cancer

January 10, 2008 - Transgene(Euronext Paris: FR0005175080) announces promising preliminary data from the Phase IIb trial evaluating its therapeutic vaccine TG4010 (MVA-MUC1-IL2) as an adjunct to first line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)... [PDF] Transgene's Press Release - PDF du communiqué de presse de Transgene, en français-